Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab with or without pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin in platinum-resistant or refractory ovarian cancer
2015-003091-77Phase 3Completed
- Sponsor
- Pfizer
- Start
- Dec 2015
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Avelumab, Avelumab + pegylated liposomal doxorubicin and Pegylated liposomal doxorubicin (3 arms). Primary endpoint: Overall survival. Started Dec 2015; status: completed.
02
Drugs
avelumabdoxorubicin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2015-003091-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003091-77.